Clinical Trials Browser

Active not recruiting × INDUSTRY × Tumor-Agnostic × Clear all

NCT04958239 2026-03-17

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

Phase 1 Active not recruiting

Neoplasms

NCT02908906 2026-03-12

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

Phase 1/2 Active not recruiting

Neoplasms

NCT05993299 2026-03-11

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Phase 2 Active not recruiting

7 enrolled 15 charts

Neoplasms

NCT05611632 2026-03-05

NHS-Galleri

Phase NA Active not recruiting

142,318 enrolled

Neoplasms

NCT06703346 2026-02-25

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Phase 2 Active not recruiting

Neoplasms

NCT00750841 2026-02-23

Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours

Phase 1 Active not recruiting

Neoplasm Metastasis

NCT05396833 2026-02-19

Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

Phase 1 Active not recruiting

Neoplasm Metastasis

NCT04078295 2026-02-10

A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

Phase 1/2 Active not recruiting

Neoplasms

NCT03260023 2026-02-05

Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

Phase 1/2 Active not recruiting

143 enrolled 24 charts

Neoplasms

NCT02584933 2026-02-03

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

Phase 4 Active not recruiting

Neoplasms

NCT06077877 2026-02-02

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

Phase 1/2 Active not recruiting

Neoplasms

NCT03964727 2026-01-30

TROPiCS-03

Phase 2 Active not recruiting

223 enrolled 31 charts

Neoplasm Metastasis

NCT04170153 2026-01-30

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Phase 1 Active not recruiting

Neoplasm Metastasis

NCT03768063 2026-01-29

IMbrella B

Phase 3 Active not recruiting

Neoplasms

NCT03096093 2026-01-20

Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer

Phase 1/2 Active not recruiting

Neoplasms

NCT03148418 2026-01-13

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

Phase 3 Active not recruiting

Neoplasms

NCT05112965 2026-01-07

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

Phase 3 Active not recruiting

Neoplasms

NCT00781612 2025-12-24

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

Phase 2 Active not recruiting

Neoplasm Metastasis

NCT05629234 2025-12-24

ROSY-T

Phase 3 Active not recruiting

Neoplasms

NCT05731271 2025-12-17

A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors

Phase 1/2 Active not recruiting

Neoplasm Metastasis

NCT06107413 2025-12-12

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

Phase 2 Active not recruiting

Neoplasms

NCT04898543 2025-12-11

QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

Neoplasm Metastasis

NCT04452955 2025-12-02

A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors

Phase 2 Active not recruiting

Neoplasms

NCT05205967 2025-11-26

REFLECTION: A Clinical Practice Learning Program for Galleri®

Active not recruiting

14,633 enrolled

Neoplasms

NCT00463814 2025-11-13

AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies

Phase 1 Active not recruiting

Neoplasms

NCT04446351 2025-10-27

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

Neoplasms

NCT04639219 2025-10-16

DPT01

Phase 2 Active not recruiting

102 enrolled 18 charts

Neoplasm Metastasis

NCT06188208 2025-10-16

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors

Phase 1 Active not recruiting

Neoplasms

NCT05898399 2025-10-15

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

Phase 1/2 Active not recruiting

Neoplasm Metastasis

NCT05374915 2025-08-28

Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)

Phase 2 Active not recruiting

Neoplasm Metastasis

NCT02099058 2025-08-14

A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

Neoplasms

NCT06547957 2025-08-13

A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

Neoplasms

NCT03415035 2025-07-16

VERONE

Active not recruiting

Neoplasms

NCT06980454 2025-07-08

Phase I PK Comparison of HLX05 vs. Erbitux® in Healthy Chinese Males: Safety, Immunogenicity, and Pharmacokinetics

Phase 1 Active not recruiting

Neoplasms

NCT04648202 2025-06-27

FS120 Phase 1/1b Study in Patients With Advanced Malignancies

Phase 1 Active not recruiting

Neoplasm Metastasis

NCT02637687 2025-06-22

SCOUT

Phase 1/2 Active not recruiting

154 enrolled 3 FDA

Neoplasms

NCT04419532 2025-04-09

A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

Neoplasm Metastasis

NCT04976634 2025-04-06

MK-6482-016

Phase 2 Active not recruiting

Neoplasms

NCT04401020 2025-03-21

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Phase 1 Active not recruiting

Neoplasms

NCT05862324 2025-02-14

TACTIC-3

Phase 1/2 Active not recruiting

Neoplasm Metastasis

NCT04050436 2025-01-27

CERPASS

Phase 2 Active not recruiting

Carcinoma, Carcinoma, Squamous Cell

NCT05155605 2024-12-30

PATHFINDER 2: a Multi-Cancer Early Detection Study

Phase NA Active not recruiting

35,885 enrolled

Neoplasms

NCT04130542 2024-10-31

Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy

Phase 1 Active not recruiting

Neoplasms

NCT04635995 2024-10-31

Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy

Phase 1 Active not recruiting

Neoplasms

NCT05548634 2024-10-23

TAVO412

Phase 1 Active not recruiting

Neoplasms

NCT06614140 2024-09-26

Personalized Neoantigen Cancer Vaccine for Patients with Solid Tumors

Phase 1/2 Active not recruiting

Neoplasms

NCT05295017 2024-09-19

LEV93A

Active not recruiting

Neoplasms

NCT04866134 2024-08-27

HERKULES-1

Phase 1/2 Active not recruiting

Neoplasm Metastasis, Neoplasms

NCT05076552 2024-08-01

A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer

Phase 1 Active not recruiting

Neoplasm Metastasis, Neoplasms

NCT05300438 2024-06-25

Phase I Study of TSN084 in Patients With Advanced Malignant Tumors.

Phase 1 Active not recruiting

Neoplasms